XML 68 R41.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Business Segments
Engineered
Materials
Acetyl ChainOther
Activities
EliminationsConsolidated
(In $ millions)
Three Months Ended March 31, 2026
Net sales1,325 1,036 — (24)(1)2,337 
Cost of sales(993)(895)(5)24 (1,869)
Gross profit332 141 (5)— 468 
Selling, general and administrative expenses(95)(26)(105)— (226)
Amortization of intangible assets(39)(1)— — (40)
Research and development expenses(18)(10)— — (28)
Other (charges) gains, net (Note 18)
(7)(9)(4)— (20)
Gain (loss) on disposition of business and assets, net48 — — — 48 
Other segment items(2)
— — 12 — 12 
Operating profit (loss)221 95 (102)— 214 
Depreciation and amortization
107 81 13 — 201 
Equity in net earnings (loss) of affiliates
31 — 35 
Capital expenditures23 20 — 44 (3)
As of March 31, 2026
Goodwill and intangible assets, net6,843 433 — — 7,276 
Total assets13,459 5,287 2,989 — 21,735 
Three Months Ended March 31, 2025
Net sales1,287 1,116 — (14)(1)2,389 
Cost of sales(1,013)(915)(1)14 (1,915)
Gross profit274 201 (1)— 474 
Selling, general and administrative expenses(108)(27)(96)— (231)
Amortization of intangible assets(40)— — — (40)
Research and development expenses(21)(10)— — (31)
Other (charges) gains, net (Note 18)
(15)(3)(13)— (31)
Gain (loss) on disposition of business and assets, net— (1)— 
Other segment items(2)
— — 21 — 21 
Operating profit (loss)94 161 (90)— 165 
Depreciation and amortization
109 61 10 — 180 
Equity in net earnings (loss) of affiliates
16 — 22 
Capital expenditures39 30 — 78 (3)
As of December 31, 2025
Goodwill and intangible assets, net
6,917 438 — — 7,355 
Total assets13,971 5,3022,422 — 21,695 
______________________________
(1)Includes intersegment sales primarily related to the Acetyl Chain.
(2)Includes Foreign exchange gain (loss), net.
(3)Includes a decrease in accrued capital expenditures of $22 million and $24 million for the three months ended March 31, 2026 and 2025, respectively.